Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells

Cells degrade proteins either by proteasomes that clinically are targeted by for example bortezomib or carfilzomib, or by formation of autophagosomes and lysosomal degradation that can be inhibited by hydroxychloroquine (HCQ). Multiple myeloma is unique among cancers because proteasomal inhibition h...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Baranowska, Katarzyna, Misund, Kristine, Starheim, Kristian K., Holien, Toril, Johansson, Ida, Darvekar, Sagar, Buene, Glenn, Waage, Anders, Bjørkøy, Geir, Sundan, Anders
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342593/
https://ncbi.nlm.nih.gov/pubmed/27683126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12226
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars